Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 13/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | RAD51 | Q06609 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BCL2 | P10415 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
| ▸ | RAD1 | O60671 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921056 | 0.89 | BCL2A1 (0.80) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13982553 | 0.88 | BCL2A1 (0.79) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912151 | 0.87 | BCL2A1 (0.77) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912138 | 0.86 | BCL2A1 (0.75) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912158 | 0.85 | BCL2A1 (1.00) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13186471 | 0.83 | RAD51 (1.00) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912142 | 0.83 | BCL2A1 (1.00) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912155 | 0.83 | BCL2A1 (1.00) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912146 | 0.82 | BCL2A1 (1.00) | BCL2A1ALDH1A1MAPTALOX12RAD51 | |
| SCHEMBL13912163 | 0.82 | BCL2A1 (0.71) | BCL2A1ALDH1A1MAPTALOX12RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | claimed |
| WO-2008157003-A2 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2008-12-24 | — | — | WO | claimed |
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2021-02-09 | — | — | US | disclosed |
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2014085545-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008157003-A2 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157003-A2 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | RAD51, MRE11, RAD50 | BCL2A1 951/4885ALDH1A1 3973/4885MAPT 2482/4885 |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | TMBIM6, BCL2L1, BCL2L11 | BCL2A1 11/4885ALDH1A1 2702/4885MAPT 3995/4885 |
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | RAD51, MRE11, RAD50 | BCL2A1 951/4885ALDH1A1 3973/4885MAPT 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.